Low-dose Prednisolone for Prevention of Recurrences in Adult Immune Thrombocytopenia (ITP)

A Randomized Multi-center Trial Comparing Low-dose Prednisolone versus Observation for Prevention of Recurrences in Adult Immune Thrombocytopenia (ITP)

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20140213002

Enrollment

Registered

2014-02-13

Start date

2014-02-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune thrombocytopenia (ITP) Immune thrombocytopenia (ITP) Prednisolone Low dose Recurrence

Interventions

Prednisolone 7.5 mg/d for 6 months then 5 mg/d for 1 month then 2.5 mg/d for 1 month then stop ,Observation

Experimental Drug,No Intervention No treatment

Prednisolone,Observation

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: ITP patients who have been treated and responsive to steroids Age over 15 years Current platelet count of 30000/uL or over

Exclusion criteria

Exclusion criteria: Secondary ITP Prednisolone dose 7.5 mg/d or below more than 3 months Refractory ITP Post-splenectomy Contra-indication to steroids

Design outcomes

Primary

Measure	Time frame
ITP recurrence 10-month follow-up Platelet count	—

Secondary

Measure	Time frame
Platelet count 10-month follow-up Platelet count	—

Countries

Thailand

Contacts

Public ContactPonlapat Rojnuckarin

Faculty of Medicine, Chulalongkorn University

rojnuckarinp@gmail.com6622564564

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Low&#45;dose Prednisolone for Prevention of Recurrences in Adult Immune Thrombocytopenia (ITP)